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Abstract
Psoriasis is a common immune mediated disorder that affects the skin, nails, and joints. To 
identify psoriasis susceptibility loci, we genotyped 438,670 SNPs in 1,409 European ancestry 
psoriasis cases and 1,436 controls. Twenty-one promising SNPs were followed-up in 5,048 
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psoriasis cases and 5,041 controls. Our results provide strong support for the association of at least 
seven genetic loci and psoriasis (each with p < 5×10−8 overall). Loci with confirmed association 
encode HLA-C, three genes involved in IL-23 signaling (IL23A, IL23R, IL12B), two genes that act 
downstream of TNF-α and regulate NF-κB signaling (TNIP1, TNFAIP3), and two genes involved 
in the modulation of Th2 immune responses (IL4, IL13). Although the proteins encoded in these 
loci are known to interact biologically, we found no evidence for epistasis between associated 
SNPs. Our results expand the catalog of genetic loci implicated in psoriasis susceptibility and 
suggest priority targets for study in other auto-immune disorders.
Psoriasis is a common inflammatory disease affecting ~1% of individuals. The most obvious 
cellular features of psoriasis are epidermal hyperplasia, altered keratinocyte differentiation, 
and inflammation1. Psoriasis susceptibility has a genetic component, partly explained by 
association between psoriasis and major histocompatibility complex (MHC) haplotypes 
bearing HLA-Cw62 and SNPs near IL12B and IL23R3. Patients with psoriasis show 
increased risk for other immune mediated disorders4 and some IL12B and IL23R 
polymorphisms are associated with Crohn’s disease and ulcerative colitis in addition to 
psoriasis (e.g.5).
To identify additional psoriasis susceptibility loci, we carried out a genome-wide association 
scan of 1,409 psoriasis cases and 1,436 controls in partnership with the Genetic Association 
Information Network (GAIN)6 (see Table 1 and Supplementary Table 1 for details of case 
and control collections). After samples were genotyped at Perlegen Sciences, we used a 
dataset that passed quality control filters and included 438,670 autosomal SNPs genotyped 
in 1,359 psoriasis cases and 1,400 controls to impute genotypes for 2.5M HapMap SNPs 
(see methods).
An initial comparison of case-control allele frequencies (genomic control λ=1.033) 
demonstrated association at established susceptibility loci HLA-C (rs12191877, p = 
4×10−53), IL12B (rs2082412, p = 5×10−10), and IL23R (rs2201841, p = 3×10−7). 
Encouraged by these results, we selected 21 SNPs (representing 18 independent loci, see 
Methods) for genotyping in an additional 5,048 cases and 5,051 controls (see Table 1 and 
Supplementary Table 2). We found supporting evidence of association at 10 of these 18 loci 
(p < 0.05 in the follow-up sample, direction of effect matches discovery sample; Table 2). 
Evidence for association was particularly compelling at seven of these loci (p < 0.0005 in 
follow-up samples, combined p-value < 5×10−8). Due to the “winner’s curse”, odds ratios 
estimated in the discovery sample were larger than those estimated in the follow-up samples. 
To minimize this effect, we use follow-up sample odds ratios in the discussion that follows. 
Figure 1 summarizes the results of the association scan, with the seven regions of confirmed 
association detailed in Figure 2. Overall, our approach provides ~70% power to detect loci 
that are well tagged by genotyped SNPs, increase disease risk by >1.35-fold and have a 
frequency >20%.
The results highlight the role of several key pathways in disease susceptibility. First, three 
SNPs exhibiting strong evidence of association map near IL12B (encoding the p40 subunit 
of IL-23 and IL-12), IL23A (encoding the p19 subunit of IL-23), and IL23R (encoding a 
subunit of the IL-23 receptor). The SNPs are rs2082412 (risk allele frequency in controls 
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fcontrol = 0.80, odds ratio in follow-up samples ORfollow-up = 1.44, combined p-value 
pcombined = 2×10−28), rs2066808 (fcontrol = 0.93, ORfollow-up = 1.34, pcombined = 1×10−9), and 
rs2201841 (fcontrol = 0.29, ORfollow-up = 1.13, pcombined = 3×10−8), respectively. Genetic 
variants in the IL23A locus are implicated in psoriasis and auto-immune disease 
susceptibility for the first time by our study. IL-23 signaling promotes cellular immune 
responses by promoting the survival and expansion of a recently identified subset of T-cells 
expressing IL-17 that protects epithelia against microbial pathogens7. Dysregulated IL-23 
signaling could predispose certain individuals to inappropriate, chronic immune responses 
that target epithelial cells and ultimately result in psoriasis.
Second, loci including TNFAIP3 (TNF-α induced protein 3) and TNIP1 (TNFAIP3 
interacting protein 1), whose gene products work downstream of TNF-α to regulate NF-κB, 
show strong association with psoriasis. In these two regions, markers rs610604 (fcontrol = 
0.32, ORfollow-up = 1.19, pcombined = 9×10−12) and rs17728338 (fcontrol = 0.05, ORfollow-up = 
1.59, pcombined = 1×10−20) were sites of replicated association. TNFAIP3 encodes A20, a 
TNF-α-inducible zinc finger protein that temporally limits immune responses by inhibiting 
NF-κB activation and terminating NF-κB mediated responses8. Symptoms in a mouse 
model of psoriasis induced by administration of IL-23 are ameliorated by blocking of TNF-
α9 and in a different mouse model, a region of mouse chromosome 10 encompassing 
Tnfaip3 promotes psoriasis in a TNF-α dependent manner10. Interestingly, this same region 
of the mouse genome has been also associated with atherosclerosis11, a major co-morbidity 
of psoriasis12. Note that both anti-IL-12/IL-23 p40 and anti-TNF-α monoclonal antibodies 
provide highly efficacious therapeutic regimens for many psoriasis patients13,14, and that 
five of the genes implicated here play key roles in pathways targeted by therapeutic 
interventions. Interestingly, common polymorphisms near TNFAIP3 have recently been 
associated with rheumatoid arthritis (e.g. rs6920220, rs10499194) (e.g.15) and systemic 
lupus erythematosus (e.g. rs5029939, rs13192841, rs2230926 and rs6922466)16,17. 
However, these polymorphisms show no association with psoriasis in our sample (all p > 
0.30) and are not in linkage disequilibrium (LD, all r2 < 0.03) with the psoriasis associated 
alleles (e.g. rs610604).
Third, genes in the two other loci implicated here are also key modulators of immune 
response. One locus encodes the IL-4 and IL-13 cytokines that modulate humoral immune 
responses mediated by Th2 cells. In this locus, we replicated association at rs20541 (fcontrol 
= 0.79, ORfollow-up = 1.27, pcombined = 5×10−15). Dysregulation of IL-4 and IL-13 might 
polarize the immune response toward Th1-mediated cellular immune responses and support 
the marked expansion of IL-17-producing T cells observed in psoriatic lesions18. Our 
findings extend the promising results of a recent study19 to a genome-wide level of 
significance. Interestingly, our IL4/IL13 signal maps within ~200kb of the IBD5 Crohn’s 
disease susceptibility locus5. The two are not in LD (e.g., r2 between rs20541 and 
rs100777855 in HapMap CEU is < .01) but IBD5 does exhibit modest evidence for 
association with psoriasis (rs10077785, p = .03) suggesting it could be another locus that 
contributes to both diseases.
SNP rs12191877, the genotyped marker exhibiting strongest association with psoriasis 
(fcontrol = 0.15, fcase = 0.30, ORfollow-up = 2.64, pcombined ≪ 10−100), was in LD with HLA-
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Cw6 (r2 = 0.63). In a subset of cases and controls in which HLA-Cw6 genotypes were 
available, HLA-Cw6 was more strongly associated with psoriasis than any genotyped or 
imputed SNP, but could not fully account for all observed association signals (data not 
shown). To assess the evidence for multiple psoriasis susceptibility alleles within the MHC, 
we implemented a forward selection procedure to select a set of disease-associated variants 
in each locus (see Methods). This analysis resulted in a model with three imputed SNPs 
(Supplementary Table 3). The first two of these (rs12204500 and rs13191343, forward 
selection p-values of 8×10−57 and 2×10−10, respectively) are close to and in strong LD with 
HLA-Cw6 (r2 = 0.78 and 0.52, respectively), whereas the third one (rs2022544, p-value = 
10−7) maps closer to HLA-DR and exhibits only weak LD with HLA-Cw6 (r2 = 0.01). These 
results endorse a search for additional psoriasis susceptibility loci within the MHC.
When we applied the same forward selection strategy to the other loci, two independent 
SNPs (r2 < 0.01) were selected in the IL12B and IL23R regions. Although only one SNP was 
selected in the four other regions (Supplementary Table 3), it is likely that independent 
disease-associated alleles exist in additional loci such as TNIP1 where rs884520 (a SNP only 
~6 kb away from the peak of association at rs17728338) was suggestively associated with 
psoriasis (p = 9 × ×10−5 unadjusted, p = 0.051 after conservatively adjusting for 565 
independent tests) in our conditional analyses. Fully characterizing the impact of these loci 
on psoriasis susceptibility will require characterization of the full spectrum of allelic 
variation at each locus in large case control samples.
Since all the loci implicated here are involved in regulation of immune responses, and 
several of the proteins they encode interact physically (e.g. IL-12B/p40, IL-23A/p19, and 
IL-23R and also TNIP1 and TNFAIP3), we assessed our data for evidence of epistasis. We 
considered all 21 possible pairings of the seven lead SNPs, testing for deviation from a log-
additive risk model. Only the pairing involving rs12191877 near HLA-C and rs610604 near 
TNFAIP3 showed any evidence for epistasis under this model (p = 0.02 in combined 
sample). It is possible that tests of interaction will be more powerful once the causal variants 
at each loci have been identified, but it is striking that even when proteins encoded by the 
associated loci interact physically no evidence for epistasis was detected (a similar situation 
occurs for height20, among other traits).
To evaluate evidence for heterogeneity in the effect sizes at each of the seven replicated loci, 
we calculated I2 and Q statistics for a meta-analysis of follow-up samples (Supplementary 
Table 4). We observed no evidence for heterogeneity at non-MHC loci, and only modest 
evidence for heterogeneity at rs12191877 in the MHC (p = 0.007, Supplementary Table 4) – 
potentially reflecting sample differences in the proportion of familial cases and psoriatic 
arthritis. At several of the confirmed loci, we found modest differences in association signal 
strength for psoriatic arthritis compared to purely cutaneous psoriasis (Supplementary Table 
5), supporting epidemiologic evidence for differences in genetic architecture of the two 
conditions21. In other stratified analyses, we found no evidence for heterogeneity between 
males and females (all p > .15) or between younger and older individuals (all p > .15, cases 
and controls stratified around median ages).
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Psoriatic and uninvolved skin show significantly different expression for hundreds of genes, 
involved in both immune response and in the regulation of cellular differentiation and 
proliferation22. We reasoned that genes in the loci implicated by our study might also play 
the role of molecular triggers in disease progression. Therefore, we examined expression 
levels for the genes showing replicated evidence of association in skin biopsies from 64 
GWAS controls and in biopsies of involved and uninvolved skin from 58 GWAS cases. The 
results are summarized in Supplementary Table 6 and in Supplementary Figure 1. Together 
these show that four of the genes investigated (HLA-C, IL12B, TNIP1 and IL23A) show 
highly significant differences in expression levels between involved and uninvolved skin (all 
with p < 10−9). Two of these (IL23A, TNIP1) also show differences in expression levels 
when we compared normal skin from controls and uninvolved skin from cases (p < 0.0003). 
The results are consistent with the hypothesis that the expression of particular HLA-C alleles 
and of IL23A and IL12B (encoding the two subunits of IL-23) in psoriatic skin, are key 
events in disease progression. However, the dosage of risk alleles at the seven psoriasis 
associated SNPs did not correlate with transcript levels for nearby genes in either involved, 
uninvolved or normal skin. It remains possible that association between these SNPs and 
gene expression patterns is stronger at specific time points during development, disease 
progression or in specific cell types.
Although this study represents a significant advance in our understanding of the genetic 
underpinnings of psoriasis, much work remains to be done. The association signals 
identified here account for a sibling recurrence risk (λs) of <1.35 (including ~1.25 due to 
HLA); consequently, much of the overall sibling recurrence risk for psoriasis, which has 
been estimated at ˜3 to 6-fold23, remains unexplained. Still, the rapid pace of advance in 
psoriasis genetics is encouraging. In the past 18 months, the number of independent genetic 
loci confidently associated with psoriasis has increased from one (HLA-Cw6 and other 
MHC variants) to at least ten, including the seven association signals reported in this paper, 
copy number variants in the beta-defensin24 and late cornified envelope (LCE) gene 
regions25, and a signal near ZNF313, a potential regulator of T cell activation26. The 
ZNF313 signal is supported by our data (see Supplementary Table 7 for analysis of 
previously reported GWAS26,27 signals in our data). Although we did not systematically 
characterize copy number variation, we note that rs4112788, a SNP proxy for the LCE 
deletion25,27, is associated with disease in our discovery sample (p = 0.001). In each of the 
loci identified here, fine-mapping and resequencing efforts together with further functional 
studies are required to pinpoint and characterize causal variants, confirm the identity of the 
implicated genes, and accurately quantify the contribution of the locus to disease 
susceptibility. In parallel, follow-up analyses with larger numbers of SNPs, execution of 
genomewide association scans in larger sample sets, meta-analyses of genomewide scan 
results, and large scale analyses of rarer variants should lead to additional susceptibility loci.
METHODS
Informed Consent
All participating subjects gave informed consent and protocols were reviewed and approved 
by local institutional review boards.
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Genotyping
Perlegen Sciences (Mountain View, CA, USA) genotyped discovery samples using four 
proprietary, high-density oligonucleotide arrays. SNPs on the arrays were selected to tag 
common variation in European ancestry samples. Cases and controls from the same 
collection were genotyped together, and arranged to ensure similar proportions of cases and 
controls in each plate. Follow-up samples were genotyped using either Applied Biosystems 
Taqman assays, Sequenom single base extension assays, or allele-specific kinetic PCR. The 
21 SNPs selected for follow-up included nineteen SNPs selected to represent loci exhibiting 
strongest evidence for association in our initial scan (including 2 SNPs per locus for hits 
near IL13, IL23A and PRKRIP1) and two SNPs in loci that included strong functional 
candidates (IL1RN and CNTN5) but more modest evidence of association (rs397211, p = 
1×10−3, and rs12807920, p = 1×10−4).
Sample Quality Control
Eighteen samples failed genotyping for technical reasons. Among the remaining samples, 
we excluded those with call rates <95% (8 samples) and with outlier heterozygosities of 
<31% or >34% (24 samples; the average heterozygosity for all samples was 32.6% with 
standard deviation of 0.4%). We also excluded one individual from each pair of unexpected 
duplicates, 1st or 2nd degree relatives (36 individuals). This resulted in a dataset with 1,359 
cases and 1,400 controls.
Quality Control of Genotype Data
Perlegen Sciences called >50% of genotypes for 556,383 SNPs. Before analysis, we 
excluded markers with <95% genotype call rates (99,963 SNPs), with minor allele 
frequency <1% in the combined dataset (6,106 SNPs), with HWE p-value < 10−6 (2,962 
SNPs), with >2 mismatches among 48 duplicate pairs (62 SNPs) or with >2 Mendelian 
inconsistencies among 27 trios (41 SNPs). In total, 447,249 SNPs passed the quality control 
filters (average call rate of 99.2%). Here, we present analyses of 438,670 autosomal SNPs.
Genotype Imputation
As previously described28, we used information on patterns of haplotype variation in the 
HapMap CEU samples (release 21)29 to infer missing genotypes “in silico”. We only 
analyzed SNPs that were genotyped or could be imputed with relatively high confidence 
(estimated r2 between imputed SNP and true genotypes > 0.3; so that patterns of haplotype 
sharing between sampled individuals and HapMap samples consistently indicated a specific 
allele).
Assessment of Genotyping and Imputation Quality
A single plate containing 90 study samples was re-genotyped for 906,600 SNPs using the 
Affymetrix 6.0 chip. Comparison of 15,844,334 genotypes for 218,039 SNPs overlapping 
between the Perlegen and Affymetrix platforms resulted in an observed discrepancy rate of 
0.25% per genotype (0.12% per allele). Comparison of 57,747,244 imputed and 
experimentally derived genotypes for 661,881 non-Perlegen SNPs present in both our 
imputed SNP set and the Affymetrix 6.0 array resulted in a discrepancy rate of 1.80% per 
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genotype (0.91% per allele). Overall, the average r2 between imputed genotypes and their 
experimental counterparts, which provides an estimate of the relative power of analysis 
relying on imputation instead of direct genotyping, was 0.93. This r2 statistic exceeded 0.80 
for >90% of SNPs suggesting excellent coverage of common variation in the genome.
Association Analyses
To evaluate the evidence for association between each genotyped or imputed SNP and 
psoriasis, we first calculated a single chi-squared statistic that contrasted observed or 
imputed allele counts between cases and controls. The 832 follow-up samples collected by 
Judith Fischer (see Table 1) and her colleagues were analyzed using a family-based 
approach30. To combine statistics across different samples, we first selected an arbitrary 
reference allele for each marker and then calculated a z-statistic characterizing the evidence 
for association in each study (summarizing both the p-value, in its magnitude, and the 
direction of effect, in its sign). We then calculated an overall z-statistic as a weighted 
average of the individual statistics and calculated the corresponding p-value. Weights were 
proportional to the square root of the number of individuals examined in each sample and 
were selected such that the squared weights sum to 1.0.
Conditional Analyses
We first selected the SNP exhibiting strongest association in each region. Then, conditioning 
on this SNP, we searched for the next most strongly associated SNP. If evidence for 
association at this second SNP was stronger than expected by chance (after adjusting for the 
number of SNPs tested), we sought a third strongly associated SNP and so forth.
Gene Expression
Six millimeter punch skin biopsies were obtained at the University of Michigan Department 
of Dermatology. One biopsy of normal skin was obtained from the buttock of 64 control 
individuals. Two biopsies (one involved, one uninvolved) were obtained from 58 psoriatic 
subjects. Involved skin biopsies were taken from psoriasis plaques, and uninvolved skin 
biopsies were taken from the buttocks, at least 10 cM away from the nearest plaque. RNA 
from each biopsy was isolated using the RNeasy kit (Qiagen). Samples were run on 
Affymetrix U133 Plus 2.0 arrays to evaluate expression of ~54,000 probes according to the 
manufacturer’s protocol. The raw data from 180 microarrays was processed using the 
Robust Multichip Average (RMA) method. Prior to analysis, we adjusted RMA expression 
values to account for batch and sex effects. To obtain a single expression value for each 
gene, we calculated the average of expression values of multiple probe sets on the 
microarray that were mapped to the same gene. Gene expression was contrasted between 
different groups of samples using two sample T-tests (for comparisons involving skin from 
normal controls and individuals with psoriasis) or paired T-tests (for comparisons involving 
involved and uninvolved skin from affected individuals). Comparisons of normal skin from 
controls and psoriatic skin from cases gave similar results (but slightly more significant p-
values) to paired comparisons of involved and uninvolved skin from the same affected 
individual and are not shown. Re-analysis of a previously published dataset22 including 
paired biopsies of involved and uninvolved skin from 16 individuals gave results consistent 
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with those reported here, suggesting that IL23A, IL12B and TNIP1 are over-expressed in 
involved skin. This independent dataset did not suggest differential expression of HLA-C.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Bird’s Eye View of Association Scan Results
The top panel summarizes the distribution of test statistics at genotyped SNPs across the 
genome. We used a simple chi-squared test to compare SNP allele frequencies in cases and 
controls and plotted the resulting -log p-values across the genome. Several p-values < 10−20 
in the MHC region were truncated. Loci where we obtained confirmatory evidence of 
association in follow-up samples (see Table 2) are highlighted in green.
The middle panel summarizes the distribution of test statistics across the genome, after 
genotype imputation. We used a simple t-test to compare imputed allele counts in cases and 
controls and plotted the resulting –log p-values across the genome.
The bottom panel displays a Q-Q plot for our test statistics. Results are plotted including all 
SNPs (in red), after excluding SNPs in the MHC (in orange) and after excluding all SNPs in 
regions of replicated association (in blue). The shaded region represents a 90% confidence 
interval for the test statistics.
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Figure 2. Evidence for Association in Confirmed Loci
The figure summarizes evidence of association (in the discovery sample) in each region of 
confirmed association. Test statistics at the SNP selected for follow-up (typically, the 
genotyped SNP exhibiting strongest evidence for association in each locus) are highlighted 
with a square. Test statistics for other SNPs are drawn as circles and color coded according 
to the degree of linkage disequilibrium with the SNP selected for follow-up.
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